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Abstract
Background: Patients with chronic kidney disease (CKD) are at high risk of progression to end stage renal disease
and cardiovascular events. Physical activity may reduce these risks by improving metabolic health. We tested
associations of physical activity with central components of metabolic health among people with moderate-severe
non-diabetic CKD.
Methods: We performed a cross-sectional study of 47 people with CKD (estimated GFR <60 ml/min/1.73 m2) and
29 healthy control subjects. Accelerometry was used to measured physical activity over 7 days, the hyperinsulinemic-
euglycemic clamp was used to measure insulin sensitivity, and DXA was used to measured fat mass. We tested
associations of physical activity with insulin sensitivity, fat mass, blood pressure, serum lipid concentrations, and
serum high sensitivity C-reactive protein concentration using multivariable linear regression, adjusting for possible
confounding factors.
Results: Participants with CKD were less active than participants without CKD (mean (SD) 468.1 (233.1) versus 662.3
(292.5) counts per minute) and had lower insulin sensitivity (4.1 (2.1) versus 5.2 (2.0 (mg/min)/(μU/mL)), higher fat mass
(32.0 (11.4) versus 29.4 (14.8) kg), and higher triglyceride concentrations (153.2 (91.6) versus 99.6 (66.8) mg/dL). With
adjustment for demographics, comorbidity, medications, and estimated GFR, each two-fold higher level of physical
activity was associated with a 0.9 (mg/min)/(μU/mL) higher insulin sensitivity (95% CI 0.2, 1.5, p = 0.006), an 8.0 kg lower
fat mass (−12.9, −3.1, p = 0.001), and a 37.9 mg/dL lower triglyceride concentration (−71.9, −3.9, p = 0.03). Associations
of physical activity with insulin sensitivity and triglycerides did not differ significantly by CKD status (p-values for
interaction >0.3).
Conclusions: Greater physical activity is associated with multiple manifestations of metabolic health among people
with moderate-severe CKD.
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Background
People with chronic kidney disease (CKD) are at high
risk of cardiovascular disease (CVD) [1]. Reduced sensi-
tivity to the actions of insulin, i.e. insulin resistance, is
one mechanism through which CKD may promote CVD
[2]. Patients with CKD are often insulin resistant [3–5].
Insulin resistance is a central component of the metabolic
syndrome, an adverse metabolic milieu that includes obes-
ity, hyperglycemia, dyslipidemia, and hypertension and
is associated with activation of the renin-angiotensin-
aldosterone system, oxidative stress, inflammation, and
endothelial dysfunction [2, 6, 7]. Insulin resistance and
these interrelated metabolic abnormalities have been
associated with increased risks of atherosclerosis and
cardiovascular events as well as progression of CKD to
end stage renal disease [8–11].
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Interventions that aim to increase physical activity are
promising approaches to improve metabolic health and
clinical outcomes in CKD. In people without CKD, phys-
ical activity reduces adiposity and mitigates the metabolic
syndrome [12, 13]. In the CKD population, physical ac-
tivity is often low, and greater higher physical activity is
associated decreased risks of CKD progression [14] and
mortality [15]. However, few studies have assessed the
metabolic pathways through which physical activity
may lead to improved outcomes in CKD.
We quantified physical activity using accelerometers in
a cross-sectional study of people with and without
moderate-severe CKD, none of whom had clinical dia-
betes [4]. We examined relationships of objectively mea-
sured physical activity with insulin sensitivity quantified
using the gold standard hyperinsulinemic-euglycemic
clamp [16] and with related measures of metabolic health.
We hypothesized that higher levels of physical activity
would be associated with greater insulin sensitivity, re-
duced adiposity, an improved lipid profile, lower blood
pressure, and lower levels of systemic inflammation.
Methods
Study population
The Study of Glucose and Insulin in Renal Disease
(SUGAR) is a cross-sectional study of glucose and insu-
lin metabolism among individuals who have moderate-
severe nondiabetic CKD and healthy control individuals
who do not have kidney disease [4]. Participants were re-
cruited from nephrology and primary care clinics associ-
ated with the University of Washington and neighboring
institutions in Seattle, Washington, from 2011 to 2104
(Additional file 1: Figure S1). SUGAR enrolled 59 par-
ticipants with non-diabetic stage 3–5 CKD (estimated
glomerular filtration rate <60 mL/min/1.73 m2 not
treated with dialysis) and 39 control subjects (estimated
glomerular filtration rate >60 mL/min/1.73 m2) with
comparable distributions of age, sex, and race. Exclusion
criteria for both groups included age <18 years, a clinical
diagnosis of diabetes, maintenance dialysis or fistula in
place, history of kidney transplantation, use of medications
known to reduce insulin sensitivity (including corticoste-
roids and immunosuppressants), fasting serum glucose
≥126 mg/dL, and hemoglobin <10 g/dL. For this study, we
included 76 SUGAR participants who collected accelero-
metry data for ≥480 min on each of three or more days,
excluding 12 who did not perform accelerometry and 10
whose accelerometry data were insufficient.
Accelerometry
We quantified physical activity using the ActiGraph
GT3X. The GT3X measures movement in three planes
(x-axis, y-axis, z-axis). Movements in all three planes
were summed for each 60-s time period (1-min epoch)
to generate movement in counts per minute (CPM).
Study participants were asked to wear an accelerometer
at their waist at all times through a consecutive 7-day
period, including weekdays and weekend days, removing
the accelerometer only during sleep and water-based ac-
tivities. ActiLife v5.10.0 was used to upload, clean, and
analyze collected data.
Accelerometry data reduction and analysis were based
on prior reports [17, 18]. Participants were included in
analyses if they wore an accelerometer for at least 8 h
(approximately 60% of wake time) on at least 3 days (ap-
proximately half of the requested number of wear days).
Non-wear periods were defined as intervals of at least
60 min during which no more than 2 min registered
greater than zero CPM and no single minute registered
>100 CPM. For each sufficient participant-day, CPM was
calculated as the total number of movement counts di-
vided by total wear time. For each participant with at least
three qualified wear days, we calculated mean CPM, the
primary exposure for this study, as the simple mean of
CPM for all days with sufficient data. As secondary expo-
sures, we also examined proportions of time spent active
(i.e. non-sedentary) and in moderate-vigorous physical
activity [18]. For each minute of wear time, ≤59 CPM
was classified as sedentary, and >59 CPM was classified
as active.
Participants also completed the Human Activity Profile
(HAP) as a parallel assessment of self-reported physical
activity, and the adjusted HAP score was used as a third
exposure [19].
Metabolic health
Insulin sensitivity was measured using by hyperinsulinemic-
euglycemic clamp [4], based on the method of DeFronzo et
al. [16]. Participants were admitted to the University of
Washington Clinical Research Center after an overnight
fast. An insulin infusion was administered as a prime
(160 mU/m2/min for 5 min) followed by a constant in-
fusion (80 mU/m2/min). Blood glucose was measured
every 5 min, and a variable rate of unlabeled 20% dextrose
was infused to maintain blood glucose at approximately
90 mg/dL. Beginning 120–150 min after initiation of the in-
sulin infusion, the dextrose infusion rate was held constant
for 30 min, over which three steady-state plasma samples
were obtained 15 min apart. Plasma concentrations of insu-
lin and glucose were measured by two site immune-
enzymometric assay (Tosoh 2000 auto-analyzer) and the
glucose hexokinase method (Roche Module P Chemistry
autoanalyzer), respectively. The dextrose concentration of
the infusate was similarly quantified. Insulin sensitivity (SI)
was calculated as (glucose disposal rate adjusted for drift in
plasma glucose x concentration of infused glucose)/(insulin
concentration at steady state – fasting insulin concentra-
tion) [16]. We calculated HOMA-IR from fasting insulin
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and glucose concentrations as an alternate assessment of
insulin resistance [20].
Body composition (fat mass and fat-free mass) was
measured by DXA (GE Lunar or Prodigy and iDXA, En-
Core Software versions 12.3 and 14.1). Quality assurance
procedures were followed on a daily basis as the calibra-
tion block and spine phantom were scanned and the an-
alyzed readings were ensured to be within 1.5% of the
actual measured quantities.
Blood pressure (BP) was measured on two occasions
(immediately prior to the hyperinsulinemic-euglycemic
clamp and approximately 1 week later). On each occasion,
BP was measured three times, 5 min apart, in the seated
position. The mean values of the final two measurements
from each visit were used for analysis.
High sensitivity C-reactive protein (CRP), total choles-
terol, HDL cholesterol, and trigylcerides were measured
on the Beckman DXC600 automated chemistry platform
systems. SYNCHRON systems quantitatively measures
C-reactive protein, total cholesterol, HDL cholesterol,
and triglycerides in human serum or plasma by rate turbid-
ity. For all assays, interassay coefficients of variation were
less than 5%.
Covariates
Demographics and medical history were self-reported.
Prevalent cardiovascular disease was defined as a physician
diagnosis of myocardial infarction, stroke, resuscitated
cardiac arrest, or heart failure or a history of coronary
or cerebral revascularization [4]. Medications were
ascertained by the inventory method. Serum creatinine
and cystatin C were measured in fasting serum collected
immediately prior to the clamp using a Beckman DxC au-
tomated chemistry analyzer. Creatinine concentration was
traced to isotope dilution mass spectrometry values and
cystatin C concentration was calibrated to ERM-DA471/
IFCC. GFR was estimated from creatinine and cystatin C
concentrations using the CKD-EPI formula [21]. Urine al-
bumin was measured using a turbidimetric method on a
Beckman Dxc automated chemistry analyzer (interassay
coefficient of variation 0.8–1.7%).
Statistical analysis
Participant characteristics and measures of metabolic
health were summarized by tertiles of physical activity.
Scatterplots with linear regression lines were used to
graphically examine associations of physical activity with
metabolic health outcomes, stratified by CKD status.
Multivariable linear regression was used to test associa-
tions of every doubling of physical activity with metabolic
health outcomes, assessing the full study population to-
gether for primary analyses. A series of nested models
was created accounting for potential confounding co-
variates. The first model adjusted for demographic data:
age (continuous variable), sex, and race (white/black/
other). The second model additionally adjusted for car-
diovascular disease and eGFR (continuous variable).
The third model additionally adjusted for fat mass
(continuous variable), which was considered either a
confounder or mediator of the associations of interest.
Medications were included in models if they directly
affect the metabolic variable being assessed. Specific-
ally, lipid-lowering medication classes were included as
covariates when modeling triglycerides or HDL choles-
terol as an outcome and antihypertensive medications
(yes/no categorical variable plus number of medications
modeled as a continuous variable) when modeling BP
as an outcome. Missing data were multiply imputed and
combined using Rubin’s rules. Interaction terms were used
to test for differences in associations by CKD status. Two-
way interactions were tested using multiplicative terms in
the regression models with Wald tests to evaluate signifi-
cance. All analyses were performed using Stata 14.0 and R
version 3.2.1 [22]. Study investigators and staff were not
blinded to CKD status, accelerometer data, or measures of
metabolic health.
Results
Of the 76 SUGAR participants included in this study,
mean age was 62.6 years, 44.7% were female, and race
was self-reported as black for 14.5% and Asian or Pacific
Islander for 5.3% (Table 1). 47 participants had CKD and
29 did not. Characteristics of the 76 SUGAR participants
included in this analysis were similar to those of the
22 SUGAR participants excluded from this analysis
(Additional file 1: Table S1). Participants with greater
physical activity tended to be younger, weighed less,
and had a higher eGFR (Table 1). Among participants
with CKD, mean eGFR was 38.7 mL/min/1.73 m2 and
median AER was 39.2 mg/24 h (Additional file 1: Table
S2). Participants with CKD were less physically active than
participants without CKD (Fig. 1 and Additional file 1:
Table S2).
Physical activity was positively correlated with insulin
sensitivity and serum HDL cholesterol concentration and
negatively correlated with fasting insulin concentration,
HOMA-IR, fat mass, SBP, serum CRP and triglyceride
concentrations (Table 2). Adjusting for demographics, car-
diovascular disease, and eGFR (Model 2) each doubling of
CPM was associated with a 0.9 (mg/min)/(μU/mL) higher
insulin sensitivity (95% CI 0.2,1.5 (mg/min)/(μU/mL),
p = 0.006), an 8 kg lower fat mass (95% CI −12.9, −3.1 kg,
p = 0.001), and a 37.9 mg/dL lower triglyceride concentra-
tion (95% CI −71.9, −3.9 mg/dL, p = 0.03) (Table 3). With
further adjustment for fat mass (Model 3), the associations
of physical activity with insulin sensitivity and triglycerides
were modestly attenuated, and only the association with
insulin sensitivity remained statistically significant (0.7
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(mg/min)/(μU/mL) per doubling of CPM, 95% CI 0, 1.4
(mg/min)/(μU/mL), p = 0.04). Associations of physical
activity with SBP, HDL cholesterol, and CRP were not
significant in adjusted analyses. When mean CPM was
replaced with active time (versus sedentary time) or
moderate-vigorous as the exposure of interest, the re-
sults were similar with no significant changes to inter-
pretation (Additional file 1: Tables S3–S5). When mean
CPM was replaced with Adjusted Human Activity Pro-
file score (HAP) as the primary exposure of interest, as-
sociations with insulin sensitivity and triglycerides were
weaker (Additional file 1: Table S6).
Compared to non-CKD control subjects, participants
with CKD had lower mean insulin sensitivity (-1.1 (mg/
min)/(μU/mL)), higher mean total fat mass (+2.6 kg),
and higher mean triglycerides (+53.6 mg/dL) (Table 4).





(375 < CPM≤ 631)
Tertile 3
(> 631 CPM)
N 25 25 26
Demographics:
Age (years) 69.5 (10.5) 63.0 (12.5) 58.1 (11.2)
Female sex 9 (36) 11 (44) 14 (54)
Race
White 20 (80) 21 (84) 20 (77)
Black 4 (16) 2 (8) 5 (19)
Other 1 (4) 2 (8) 1 (4)
Medical history & lifestyle:
Cardiovascular disease 13 (52) 2 (8) 3 (12)
Current smoking 5 (20) 1 (4) 5 (19)
Physical activity (adjusted activity score), median 67.0 (57.0–73.0) 76.0 (71.0–82.0) 78.5 (74.5–82.8)
Average Sedentary vs Active Time (%) 74.5 63.0 49.8
Medication use:
Any antihypertensive medication 20 (80) 16 (64) 16 (62)
Number of antihypertensive medications 2.3 (1.5) 1.5 (1.8) 1.3 (1.5)
Any lipid-lowering medication 9 (36) 8 (32) 5 (19)
Statin 9 (36) 8 (32) 4 (15)
Fibrate 3 (12) 1 (4) 1 (4)
Niacin 2 (8) 0 (0) 1 (4)
Physical characteristics:
Height (cm) 172.5 (9.3) 170.5 (10.0) 173.5 (11.8)
Weight (kg) 94.9 (20.1) 85.8 (15.4) 80.1 (20.8)
Fat mass (kg) 35.7 (13.3) 31.2 (12.4) 26.3 (11.3)
BMI (kg/m2) 31.8 (6.2) 29.6 (5.3) 26.4 (5.3)
Systolic blood pressure (mm Hg) 135.1 (14.4) 130.7 (12.1) 124.3 (17.2)
Diastolic blood pressure (mm Hg) 78.0 (9.6) 79.9 (8.4) 77.4 (11.3)
Laboratory data:
Serum creatinine (mg/dL), median 1.6 (1.2–1.9) 1.4 (1.0–1.8) 1.0 (0.8–1.5)
Serum cystatin C (mg/L), median 1.6 (1.1–2.0) 1.2 (1.0–1.6) 1.0 (0.8–1.4)
Estimated GFR (mL/min/1.73 m2) 44.7 (21.7) 54.8 (28.4) 71.6 (26.5)
eGFR < 60 mL/min.1.73 m2 21 (84) 15 (60) 11 (42)
Urine AER, (mg/24 h) median 24.6 (8.2–137.4) 9.7 (5.3–91.7) 8.9 (5.6–95.4)
Mean (SD) presented for continuous variables, and median (IQR) as noted; N (%) presented for all categorical variables. Values were missing for fat mass (N = 4)
and Urine AER (N = 3). CPM counts per minute, GFR glomerular flow rate, AER Albumin excretion rate
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The associations of physical activity with insulin sensitiv-
ity and triglycerides did not differ significantly among
participants with and without CKD (Fig. 2 and Table 4).
However, the association of physical activity with fat
mass appeared weaker among participants with CKD,
with a p-value for interaction that was of borderline
statistical significance (p = 0.045 without accounting for
multiple comparisons).
Discussion
In this study, we found that higher levels of physical ac-
tivity, measured using gold standard accelerometry, were
associated with greater insulin sensitivity, lower fat mass,
and lower serum triglyceride concentration. These asso-
ciations were independent of demographics, cardiovas-
cular disease, and eGFR and were similar when physical
activity was evaluated as average daily movement (CPM)
or as proportion of time spent non-sedentary. Partici-
pants with CKD tended to have lower physical activity
and insulin sensitivity and higher fat mass and serum tri-
glyceride concentrations, compared with healthy control
subjects. Nonetheless, associations of physical activity with
metabolic health outcomes were generally similar among
participants with and without CKD.
Prior studies have shown that patients with CKD are
less physically active than the general population, an ob-
servation that we also made in our study [23]. Moreover,
among people with CKD, greater physical activity has
been associated with decreased risks of CKD progres-
sion, cardiovascular events, and mortality [24–26]. In
the general population, physical activity has been corre-
lated with reduced risks of diabetes, stroke, coronary ar-
tery disease, congestive heart failure, and hypertension
[14, 23, 24, 27, 28]. In this context, our results help de-
fine a plausible biologic basis for the potential clinical
benefits of physical activity in CKD. Specifically, our
study provides precise, quantitative data demonstrating
independent associations of physical activity with major
components of metabolic health that may mediate effects
of physical activity on long-term clinical outcomes. Our
results are complementary to and consistent with those of
the cohort studies noted above and with exercise training
studies suggesting that increased activity decreases adipos-
ity and inflammation in CKD [29].
Insulin sensitivity is an important measure of metabolic
health, with lower sensitivity (insulin resistance) compris-
ing a core component of the metabolic syndrome [30].
This study demonstrated that physical activity is directly
correlated with insulin sensitivity, using gold standard
measurements of each. The association of physical activity
with insulin sensitivity was significant after adjustment
for demographic variables, prevalent cardiovascular dis-
ease, and eGFR, but somewhat attenuated with further
adjustment for fat mass. This observation suggests that
Fig. 1 Physical activity among participants with and without CKD.
Boxplots compare the physical activity of non-CKD vs CKD partici-
pants. Physical activity was quantified as accelerometry counts per
minute (panel a), accelerometry active time (panel b), or human ac-
tivity profile adjusted activity score (panel c). Box plots display me-
dian with the 25 and 75th percentiles, with participants outside 1.5
times the IQR noted as data points
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the relationship of physical activity with insulin sensi-
tivity is mediated partly, but not wholly, through re-
duced adiposity. The hyperinsulinemic-euglycemic
clamp measures total body insulin sensitivity, which
mostly reflects skeletal muscle insulin sensitivity be-
cause endogenous glucose production by the liver is
nearly or fully suppressed at the insulin infusion rate
we applied [4]. It is therefore possible that our observed
association of physical activity with insulin sensitivity
reflects beneficial effects of exercise on muscle metab-
olism. It is also possible that insulin sensitivity is influ-
enced by other comorbidities not accounted for in this
study. The association of physical activity with insulin
sensitivity was significant when evaluated within CKD
participants only, and we did not observe an interaction
of physical activity with CKD status, suggesting that









Insulin sensitivity (mg/min)/(μU/mL) 3.8 (1.5) 4.5 (2.8) 5.2 (1.8) 0.009
Fasting glucose (mg/dL) 103.2 (8.9) 103.2 (10.0) 98.8 (8.6) 0.12
Fasting insulin (uU/mL) 11.1 (5.4) 9.7 (5.6) 6.6 (4.6) 0.004
HOMA-IR 2.8 (1.9) 2.4 (1.6) 1.5 (1.1) 0.003
Fat mass (kg) 35.7 (13.3) 31.2 (12.4) 26.3 (11.3) 0.03
BMI (kg/m2) 31.8 (6.2) 29.6 (5.3) 26.4 (5.3) 0.002
CRP (mg/dL), median 0.2 (0.2–0.4) 0.2 (0.1–0.6) 0.1 (0.1–0.3) 0.07
HDL (mg/dL) 52.2 (28.0) 50.6 (14.4) 61.2 (18.4) 0.06
Triglycerides (mg/dL), median 135.0 (114.0–191.0) 120.0 (73.0–163.0) 85.0 (58.5–120.2) 0.007
Systolic blood pressure (mm Hg) 135.1 (14.4) 130.7 (12.1) 124.3 (17.2) 0.046
Diastolic blood pressure (mm Hg) 78.0 (9.6) 79.9 (8.4) 77.4 (11.3) 0.61
Entries are mean (SD), except as noted. Some values were missing for Matsuda (N = 1), CRPH (N = 1) and Fat Mass (N = 4). CPM counts per minute, CRP high
sensitivity C-reactive protein, BMI body mass index, HDL high density lipoprotein cholesterol
Table 3 Associations of physical activity with metabolic health outcomes in SUGAR
Unadjusted Model 1 Model 2 Model 3
Outcomes:
Insulin sensitivity (mg/min)/(μU/mL) 1.0 (0.4, 1.5) 0.8 (0.2, 1.4) 0.9 (0.2, 1.5) 0.7 (0.0, 1.4)
P Value 0.0003 0.009 0.006 0.04
Fat mass (kg) −6.3 (−10.3, −2.2) −8.2 (−12.8, −3.6) −8.0 (−12.9, −3.1) NA
P Value 0.002 0.0005 0.001 NA
BMI (kg/m2) −2.7 (−4.6, −0.8) −3.6 (−5.8, −1.5) −3.6 (−5.9, −1.3) NA
P Value 0.005 0.0007 0.002 NA
CRP (% difference) −33 (−51, −7) −32 (−50, −6) −24 (−48, 13) −5 (−37, 43)
P Value 0.01 0.02 0.17 0.83
HDL (mg/dL) 5.6 (−2.3, 13.5) 6.6 (−2.0, 15.3) 6.8 (−0.8, 14.4) 5.5 (−1.5, 12.5)
P Value 0.17 0.13 0.08 0.12
Triglycerides (mg/dL) −39.9 (−72.4, −7.5) −45.0 (−76.2, −13.9) −37.9 (−71.9, −3.9) −22.7 (−57.0, 11.6)
P Value 0.02 0.005 0.03 0.20
Systolic BP (mm Hg) −5.8 (−10.7, −1.0) −4.5 (−9.1, 0.0) −3.0 (−8.0, 2.0) 0.2 (−4.6, 5.1)
P Value 0.02 0.053 0.24 0.93
Diastolic BP (mm Hg) 0.3 (−2.9, 3.5) −1.2 (−4.1, 1.7) −1.1 (−4.2, 1.9) −0.5 (−3.5, 2.6)
P Value 0.87 0.42 0.47 0.77
Entries are the difference (95% CI) in the outcome associated with a doubling in accelerometry mean counts per minute. Model 1 adjusts for age, sex, and race
(white/black/other). Model 2 additionally adjusts for cardiovascular disease and eGFR. For HDL and triglycerides outcomes, Model 2 additionally adjusts for statins,
fibrates, and niacin medications; for BP outcomes, Model 2 additionally adjusts for the number of hypertension medications. Model 3 adjusts for Model 2 variables
plus fat mass. BMI body mass index, CRP C-reactive protein, HDL high density lipoprotein cholesterol, BP blood pressure
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physical activity may be associated with improving in-
sulin sensitivity.
The inverse association of physical activity with fat
mass appeared weaker in participants with versus with-
out CKD. Associations of adiposity with mortality have
also been reported to be weaker in people with versus
without CKD [31, 32], suggesting that CKD may alter
both the causes and consequences of obesity. However,
our observed interaction was of borderline statistical sig-
nificance, particularly considering the fact that we tested
multiple potential interactions, and may not represent a
true difference by CKD status. Adiposity may promote
cardiovascular disease and progression of kidney disease
through inflammation and impaired lipoprotein metabol-
ism [33–35]. Therefore, physical activity may reduce adi-
posity, which may lead to a reduction in cardiovascular
disease and progression of kidney disease. Physical activity
was also correlated with serum triglyceride concentration.
Triglycerides may have direct lipotoxic actions on kidney
and vascular tissue and may promote kidney and vascular
disease through increased inflammation [36, 37].
We did not observe statistically significant associations
of physical activity with inflammation or blood pressure.
Other studies have shown inverse correlations of physical
ability [27] measured by questionnaire with physical activ-
ity [14] to reduced levels of CRP. We may not have shown
a significant association because of limited power and the
use of only one inflammatory marker. Also, we examined
levels of CRP in the blood, while the mechanism of action
might be in relevant tissues like adipose and muscle. BP
may not have shown correlation due to physical activity
being only one of many possible influences affecting BP,
making it difficult to find a signal among much noise. We
may have been able to detect associations with more pre-
cise 24 h ambulatory BP measurements. We observed
trends toward expected associations with CRP and BP that
may have been statistically significant in a larger study.
Physical activity (CPM) and active time yielded similar
metabolic outcome associations, with adjusted HAP
yielding weaker associations. This suggests that HAP
may misclassify physical activity and that studies that
used HAP may have had more impressive associations
had physical activity been directly measured by acceler-
ometer. Although physical activity (CPM) and active
time yielded similar outcome associations, it is difficult
to determine which is more beneficial due to the small
study size and the correlation between these two aspects
of movement within our study. A larger study has exam-
ined the concept in relationship with mortality in greater
detail and found a decrease in mortality with increased
physical activity and duration of activity [24].
Several factors contribute to the strengths and limita-
tions of our study. Accelerometry is the gold standard
for objectively measuring physical activity as it is more
precise and less subject to recall bias than question-
naires, which have been used in most prior studies
[18, 38]. The hyperinsulinemic-euglycemic clamp is a
gold standard method for the measurement of insulin
sensitivity and as such is a strength of our study. How-
ever, the accelerometer does not account for potential
inaccuracies caused by missing data due to patients
not wearing the devices. Also the wear period may not
accurately reflect a patient’s extended physical activity.
Our study is further strengthened by our examination
of a clinic-based population of importance to practicing
nephrologists and the evaluation of a comprehensive set
of metabolic outcomes that may be key mediators of
cardiovascular and renal risk in CKD patients. The
cross-sectional design of the study limits our ability to
ascertain long-term clinical outcomes or discern causal
relationships. The modest size of our study may in-
crease the influence of outliers, reduce statistical power,
and increase the chance that factors important to this
population were missed.
Table 4 Associations of physical activity with metabolic health outcomes in SUGAR, by CKD status
Dependent variable CKD Non CKD
Mean (SD)b Adjusted difference (95% CI)a Mean (SD)b Adjusted difference (95% CI)a P value for Interaction
Insulin sensitivity (mg/min)/(μU/mL) 4.1 (2.1) 0.8 (0.2, 1.4) 5.2 (2.0) 1.0 (0.1, 1.9) 0.73
Fat mass (kg) 32.0 (11.4) −4.9 (−10.2, 0.4) 29.4 (14.8) −13.2 (−20.2, −6.2) 0.045
BMI (kg/m2) 30.0 (5.5) −2.0 (−4.5, 0.6) 28.0 (6.8) −6.3 (−9.4, −3.2) 0.03
CRP (percent difference) 0.3 (2.6) −11 (−44, 43) 0.1 (2.8) −41 (−66, 2) 0.26
HDL (mg/dL) 52.4 (22.4) 2.2 (−8.2, 12.6) 58.7 (18.9) 13.9 (5.8, 22.0) 0.07
Triglycerides (mg/dL) 153.2 (91.6) −39.8 (−90.3, 10.8) 99.6 (66.8) −30.7 (−57.9, −3.5) 0.76
Systolic BP (mmHg) 134.5 (14.3) −0.2 (−6.3, 6.0) 122.6 (13.9) −7.5 (−13.1, −2.0) 0.07
Diastolic BP (mmHg) 79.6 (9.5) 1.3 (−2.4, 5.1) 76.4 (10.1) −5.2 (−8.5, −1.9) 0.007
aDifference per doubling of CPM, adjusted for age, sex, race (white/black/other), cardiovascular disease, eGFR. Lipid-lowering medications (statins, fibrates, and
niacin medications, included for HDL-cholesterol and triglycerides only), and antihypertensive medications (yes/no and number of antihypertensive medications,
for systolic and diastolic BP only), as in Model 2 of Table 3
bEntry for CRP is geometric mean (SD)
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Conclusion
In conclusion, this study suggests that greater physical
activity is associated with improved metabolic health for
patients with moderate-severe CKD by increasing insulin
sensitivity and reducing adiposity and serum triglycerides.
This study identifies insulin sensitivity, adiposity, and dys-
lipidemia as logical intermediate targets for short-term
physical activity trials that assess what types of physical ac-
tivity may best promote metabolic health in CKD. Larger
studies are needed to examine the long term effects of
physical activity and its potential health benefits for pa-
tients with CKD.
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